Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 19:9:1301.
doi: 10.3389/fphar.2018.01301. eCollection 2018.

The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development

Susan Reijntjes  1 , Muna Albayaty  2 , James Bush  3 , Joseph Cheriyan  4 , Anthea Cromie  5 , Annelize Koch  6 , Michael Hammond  7 , Stuart Mair  8 , Peter Scholes  8 , Ulrike Lorch  9 , Steffan Stringer  10 , Jorg Taubel  9 , Timothy C Hardman  1
Affiliations
Review

The Association for Human Pharmacology in the Pharmaceutical Industry London Meeting 2018: Brexit and Other Challenges in Early Phase Drug Development

Susan Reijntjes et al. Front Pharmacol. .

Abstract

The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) annual meeting focused on the changing face of early phase drug development and opened with a keynote speech concerning the revolution in pharmaceutical medicine over the last 30 years and the impact this has had on the way patients are treated. Examples were presented of how translational pharmaceutics is being used to tackle the high drug candidate failure rate and is improving productivity when moving drug candidates from the laboratory through to clinical proof of concept. The European Medicines Agency revised 2007 Risk Mitigation guideline on first in human (FIH) clinical trials was discussed. The focus of the revised guideline, which came into force in February 2018, is on risk mitigation and promotion of safety and will assist drug sponsors with the design and performance of early clinical studies. The use of integrated adaptive protocol designs in early clinical development was discussed in relation to the challenges involved when running early phase clinical trials in patients. The Health Regulatory Authority presented its strategies to ensure that following Brexit, the United Kingdom remains an attractive place to conduct Phase I clinical trials. The Medicines and Healthcare products Regulatory Agency confirmed that in the event of a "no deal" Brexit, it is well placed to implement and influence many provisions of the new EU CTR. The meeting provided an opportunity to discuss the changing regulatory environment and the opportunities and challenges facing the United Kingdom following Brexit with invited speakers from a range of disciplines including drug development, clinical trials and research organizations, government science policy and regulatory agencies.

Keywords: association for human pharmacology in the pharmaceutical industry; brexit; early phase clinical drug development; meeting report; regulatory.

PubMed Disclaimer

References

    1. ABPI (2011). The Vision for Real World Data Harnessing the Opportunities for the UK, White Paper. Available at: http://www.abpi.org.uk/about-us/resources/publications-library/vision-fo... [accessed August 08 2018].
    1. BIAL-Portela and Ca. SA-ANSM (2015). Available at: https://www.google.com/search?q=BIA+10+2474+clinical+trial+protocol&ie=u... [accessed August 07 2018].
    1. Boyce M., Walther M., Nentwich H., Kirk J., Smith S., Warrington S. (2013). TOPS: an internet-based system to prevent healthy subjects from over-volunteering for clinical trials. Eur. J. Clin. Pharmacol. 69:731. 10.1007/s00228-012-1351-1 - DOI - PubMed
    1. CHMP (2017). Committee for Medicinal Products for Human Use. EMEA/CHMP/SWP/28367/07 Rev. 1. Guideline on Strategies to Identify and Mitigate Risks for First-in-Human and Early Clinical Trials with Investigational Medicinal Products. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin... [accessed August 07 2018]. - PMC - PubMed
    1. European Commission (2014). Clinical Trials - Regulation EU No 536/2014. Available at: https://ec.europa.eu/health/human-use/clinical-trials/regulation_en [accessed July 16 2018].

LinkOut - more resources